np2
Gene therapyexperimental
Clinical trial activity
3 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Feb 1, 2008 (NCT00804076)
Timeline
Indications
Mechanism of action
- Neuronal pentraxin-2Supplementation
supplementation - nptx2
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- np2
- np2
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06171490 | N/A | Oct 20, 2023 | Philip Morris |
| NCT01291901 | Phase 2 | Jan 1, 2011 | Diamyd, invivodata, Inc., Paragon Biomedical, University of Michigan |
| NCT00804076 | Phase 1 | Feb 1, 2008 | Diamyd, University of Michigan |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Diamyd | For profit | 2 | 2 | 2 | 2008 |
| University of Michigan | Academic/Hospital | 2 | 0 | 2 | 2008 |
| invivodata, Inc. | For profit | 1 | 0 | 1 | 2011 |
| Paragon Biomedical | For profit | 1 | 0 | 1 | 2011 |
| Philip Morris | For profit | 1 | 1 | 1 | 2023 |
5 organizations
Page 1 / 1